Rhinitis, Allergic, PerennialPhase 3RINEX50NCT02988778
Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis
A Phase 3 study testing Budesonid 50mcg (Noex) and Budesonid 50mcg (Busonid) in people with Rhinitis, Allergic, Perennial, run by Eurofarma Laboratorios S.A. at 1 site in Brazil.
Trial summary
This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group. Read more about this study
- Who is it for?
- Ages 12 to 90 years
- Conditions the study is for
- Rhinitis, Allergic, Perennial
- What is being tested?
- Budesonid 50mcg (Noex) and Budesonid 50mcg (Busonid)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteBrazil
- Study dates
- 8 Oct 2019to 8 Oct 2019
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 90 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age ≥ 12
- History of allergic persistent rhinitis moderate to severe at least 2 years
- Proved allergic using PRICK or RAST test
- Nasal symptoms (NIS) > 3 and nasal obstruction >1
- Indication of nasal corticosteroids use
- Washout of nasal corticosteroids for 14 days
- ICF
Who cannot join
- Other types of rhinitis
- Asthma non controlled
- Use of oral/injectable corticoids 30 days before screening
- patients not eligible to complete diaries
- patients with allergy to any substance of medicines
- non controlled disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Phase III, Multicenter, Randomized, Simple-blinded, Parallel Groups to Evaluate Non Inferiority of Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Persistent Rhinitis Moderate to Severe
This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.
Read the detailed description
Budesonide is a medicine already very used and registered about 20 years. Eurofarma has the intention to collect more data about safety and efficacy and present them to local authority.
This study was draw to treat patients with persistent rhinitis moderate to severe in sites located locally in Brazil.
- Conditions
- Rhinitis, Allergic, Perennial
- Being tested
- Budesonid 50mcg (Noex), Budesonid 50mcg (Busonid)
- Medical subject headings
- Rhinitis, Allergic, Perennial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Budesonid 50mcg (Noex)Drug
Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Budesonid 50mcg (Busonid)Drug
Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
| Study group | Role | What they receive |
|---|---|---|
| Budesonid 50mcg (Noex) | Experimental | Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.
Treatment of 28 days. Receives: Drug: Budesonid 50mcg (Noex) |
| Budesonid 50mcg (Busonid) | Active comparator | Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.
Treatment of 28 days. Receives: Drug: Budesonid 50mcg (Busonid) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Demonstrate non inferiority of Noex using the questionnaire Nasal Index Score (NIS)
Using the questionnaire Nasal Index Score (NIS)
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2016 (estimated)
- Study start8 Oct 2019
- Primary completion8 Oct 2019
- Study completion8 Oct 2019
Why it stopped: regulatory strategy
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rhinitis, Allergic, PerennialStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eurofarma Laboratorios S.A.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Mauro Acir Crippa Junior, MD, Principal investigator, Allergisa Pesquisa Dermato-Cosmetica LTDA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02988778
- Sponsor's protocol ID
- EF149
- Acronym
- RINEX50
- Status last verified
- Aug 2017
- First submitted
- 28 Nov 2016
- Last updated
- 9 Oct 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Undecided, but could be shared upon investigator's request
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III, Multicenter, Randomized, Simple-blinded, Parallel Groups to Evaluate Non Inferiority of Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Persistent Rhinitis Moderate to Severe
- ClinicalTrials.gov ID
- NCT02988778
- Acronym / sponsor ID
- RINEX50 / EF149
- Conditions
- Rhinitis, Allergic, Perennial
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: regulatory strategy
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Eurofarma Laboratorios S.A.Industry (pharma, biotech, devices)
- Study start
- 8 Oct 2019 (actual)
- Primary completion
- 8 Oct 2019 (actual)
- Study completion
- 8 Oct 2019 (actual)
- First posted
- 9 Dec 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.
Detailed description
Budesonide is a medicine already very used and registered about 20 years. Eurofarma has the intention to collect more data about safety and efficacy and present them to local authority.
This study was draw to treat patients with persistent rhinitis moderate to severe in sites located locally in Brazil.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Budesonid 50mcg (Noex) | Experimental | Drug: Budesonid 50mcg (Noex)Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day. Treatment of 28 days. |
| Budesonid 50mcg (Busonid) | Active comparator | Drug: Budesonid 50mcg (Busonid)Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day. Treatment of 28 days. |
Who may qualify
- Ages
- 12 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥ 12
- History of allergic persistent rhinitis moderate to severe at least 2 years
- Proved allergic using PRICK or RAST test
- Nasal symptoms (NIS) > 3 and nasal obstruction >1
- Indication of nasal corticosteroids use
Key exclusion criteria (6 listed)
- Other types of rhinitis
- Asthma non controlled
- Use of oral/injectable corticoids 30 days before screening
- patients not eligible to complete diaries
- patients with allergy to any substance of medicines
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Budesonid 50mcg (Noex)Suspention to nasal use, 2 atomization in each nostril during the morning and at night. | Drug | Budesonid 50mcg (Noex) |
| Budesonid 50mcg (Busonid)Suspention to nasal use, 2 atomization in each nostril during the morning and at night. | Drug | Budesonid 50mcg (Busonid) |
Primary outcome
Demonstrate non inferiority of Noex using the questionnaire Nasal Index Score (NIS)
Time frame: 28 days
Using the questionnaire Nasal Index Score (NIS)
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2019.
- Individual participant dataSharing planned: Undecided. Undecided, but could be shared upon investigator's request
Related trials for Rhinitis, Allergic, Perennial
Active, not recruitingPhase 3
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Perennial Allergic Rhinitis (PAR)
Not yet recruitingPhase 2
Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy
Perennial Allergic Rhinitis (PAR)
RecruitingObservational study
Identification of B Regulatory Cells by Flow Cytometry
Pollen Allergy, Venom Allergy
Not yet recruitingPhase 4
A Study to Visualize Multi-Symptom Allergy in Adults With Seasonal Allergic Rhinitis
Rhinitis Allergic, Rhinitis Seasonal
Active, not recruitingPhase 2
Dupilumab Effects Against Aeroallergen Challenge
Asthma, Allergic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mauro Acir Crippa Junior, MD principal investigator
Allergisa Pesquisa Dermato-Cosmetica LTDA
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Budesonid 50mcg (Noex) and Budesonid 50mcg (Busonid) in people with Rhinitis, Allergic, Perennial, run by Eurofarma Laboratorios S.A. at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 9 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Demonstrate non inferiority of Noex using the questionnaire Nasal Index Score (NIS) (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2019.